EUCTR2006-001143-59-GB进行中（未招募）1 期
A prospective, randomised study comparing two fixed daily doses (150 IU versus 225 IU) of recombinant FSH for ovarian stimulation during in-vitro fertilisation treatment in predicted low and intermediate responders based on antral follicle count on 3D ultrasound - Randomised study of 150 IU versus 225 IU of rFSH in non-PCO women
School of Human Development0 个研究点目标入组 184 人开始时间: 2006年5月5日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 184
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •--Female subjects aged between 20 and 38 years
- •-Subjects undergoing first, second or third cycle of IVF/ICSI treatment.
- •-Subjects with basal FSH level of 10 or less.
- •-Subjects must have both the ovaries.
- •-Absence of antral follicle count ¡Ý12 with in an ovary and/or an ovary volume of >10cm3 on 3D ultrasound.
- •-Subjects who have not had any ovarian surgery in the past.
- •-Subjects, who have a body mass index (BMI) of 20 to 35
- •-Subjects in study groups must have a regular spontaneous menstrual cycle of 21 to 35 days.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Subjects who have an ovarian cyst (>20 mm) at the 1st scan in the early follicular phase. It can interfere with ovarian follicle monitoring.
- •-Subjects whose infertility caused by endocrine abnormalities such as poly cystic ovarian syndrome, hyperprolactinemia and abnormal thyroid function.
- •-Subjects with any contraindications to IVF/ICSI treatment.
- •-Subjects, who are taking concurrent corticosteroids/ Metformin.
研究者
相似试验
进行中（未招募）
1 期
A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in patients with uncontrolled hypertension who fail to respond adequately to treatment with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg.EUCTR2005-002442-19-FIBoehringer Ingelheim Finland Ky1,600
进行中（未招募）
1 期
A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in patients with uncontrolled hypertension who fail to respond adequately to treatment with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg.EUCTR2005-002442-19-ESBoehringer Ingelheim España, S.A.1,600
进行中（未招募）
1 期
A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in patients with uncontrolled hypertension who fail to respond adequately to treatment with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg.EUCTR2005-002442-19-DKBoehringer Ingelheim Ireland Ltd.1,600
进行中（未招募）
不适用
A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in patients with uncontrolled hypertension who fail to respond adequately to treatment with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg.essential hypertensionEUCTR2005-002442-19-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,600
进行中（未招募）
1 期
A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in patients with uncontrolled hypertension who fail to respond adequately to treatment with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg.essential hypertensionEUCTR2005-002442-19-IEBoehringer Ingelheim Ltd.1,600